Stock Price Movement and Market Context
On 25 Nov 2025, Indo US Bio-Tech touched an intraday low of Rs.112.6, representing a 3.43% decline on the day. This price marks the lowest level the stock has traded at in the past year, a notable contrast to its 52-week high of Rs.386. The stock has recorded losses over the last two consecutive days, with a cumulative return of -10.78% during this period.
In comparison, the broader agriculture sector, to which Indo US Bio-Tech belongs, has gained 4.27% on the same day, highlighting the stock’s relative underperformance. The sector’s positive movement contrasts with the stock’s decline, emphasising the challenges faced by Indo US Bio-Tech specifically.
Further, Indo US Bio-Tech is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests sustained downward momentum relative to its recent trading history.
Broader Market Environment
The Sensex opened higher at 85,008.93 points, gaining 108.22 points (0.13%) before trading slightly lower at 84,954.80 points (0.06%). The index remains close to its 52-week high of 85,801.70, supported by bullish signals such as the 50-day moving average trading above the 200-day moving average. Mid-cap stocks led the market with the BSE Mid Cap index rising by 0.13% on the day.
Despite the positive market environment, Indo US Bio-Tech’s stock price has not mirrored this trend, reflecting company-specific factors influencing investor sentiment and trading activity.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Financial Performance and Profitability Metrics
Indo US Bio-Tech’s recent quarterly results indicate subdued earnings performance. The Profit After Tax (PAT) for the quarter stood at Rs.3.45 crores, reflecting a decline of 22.4% compared to the average of the previous four quarters. Operating profit before depreciation, interest, and taxes (PBDIT) was recorded at Rs.4.17 crores, the lowest level in recent quarters.
The operating profit to net sales ratio for the quarter was 13.52%, also marking a low point. These figures suggest that the company’s profitability margins have contracted relative to prior periods, which may have contributed to the stock’s downward pressure.
Over the past year, Indo US Bio-Tech’s stock has generated a return of -56.35%, significantly underperforming the Sensex, which recorded a positive return of 6.03% during the same period. This divergence highlights the stock’s challenges in keeping pace with broader market gains.
Operational and Valuation Considerations
Despite the recent price decline, Indo US Bio-Tech demonstrates several positive financial attributes. The company’s return on capital employed (ROCE) stands at a robust 27.98%, indicating efficient use of capital in generating earnings. Additionally, the debt to EBITDA ratio is a modest 0.91 times, reflecting a manageable level of leverage and a strong ability to service debt obligations.
Net sales have grown at an annual rate of 31.50%, signalling healthy long-term revenue expansion. The company’s valuation metrics also suggest an attractive position relative to peers, with an enterprise value to capital employed ratio of 2.3 and a ROCE of 16.4% noted in valuation assessments.
Profit growth over the past year has been recorded at 43.9%, contrasting with the stock’s negative price return. The price/earnings to growth (PEG) ratio is 0.3, which may indicate that the stock is trading at a discount compared to historical valuations of similar companies in the sector.
Why settle for Indo US Bio-Tech ? SwitchER evaluates this Other Agricultural Products micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Shareholding and Industry Position
Indo US Bio-Tech operates within the Other Agricultural Products industry and sector. The company’s majority shareholding is held by promoters, which may influence strategic decisions and long-term planning.
While the stock’s recent performance has been subdued, the company’s operational metrics and financial ratios provide a nuanced picture of its current standing within the agricultural products space.
Summary of Key Price and Performance Data
The stock’s 52-week low of Rs.112.6 contrasts sharply with its 52-week high of Rs.386, underscoring the extent of the price correction over the past year. Indo US Bio-Tech’s underperformance relative to the BSE500 index, which has returned 4.66% over the last year, further highlights the stock’s divergence from broader market trends.
On the day of the new low, the stock underperformed its sector by 7.7%, emphasising the specific pressures faced by the company’s shares despite a generally positive environment for agricultural stocks.
Conclusion
Indo US Bio-Tech’s fall to a 52-week low of Rs.112.6 reflects a combination of subdued quarterly earnings, contraction in profitability ratios, and sustained price weakness over recent sessions. Although the broader market and sector indices have shown resilience, the stock’s performance remains challenged. Financial metrics such as ROCE, debt servicing capacity, and sales growth provide a more comprehensive understanding of the company’s current position amid this price decline.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
